Study guide

14.3 Ophthalmological and Otological Effects

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

14.3 Ophthalmological and Otological Effects

Key Takeaways Explain This Topic AI

Cisplatin and carboplatin cause sensorineural ototoxicity that starts at high frequencies; cochlear radiation adds risk.

Serial audiology, early hearing support, and classroom FM systems are the school intervention—not waiting until conversational speech is lost.

Vincristine rarely causes other cranial-nerve palsies; it is not the main platinum ototoxin.

Ocular effects include steroid cataracts, cytarabine keratitis treated with prophylactic steroid drops, GVHD dry eyes, and retinoblastoma visual-outcome planning; papilledema signposts increased ICP, and radiation retinopathy is rare and delayed.

Report new hearing loss, tinnitus, photophobia, and eye pain the same day they appear.

Last updated: August 2026

TCO IV.A.12–13 tests ophthalmologic and otologic acute, chronic, and late effects. This is not the emergency intracranial-pressure (ICP) chapter. Papilledema is signposted. Here the nurse times platinum hearing loss , protects the cochlea from unacknowledged radiation, keeps audiology and school frequency-modulated (FM) systems on the map, and treats eye pain and photophobia as reportable—not as screen time.

A 3-year-old receiving cisplatin for hepatoblastoma, a 7-year-old after posterior-fossa radiation whose teacher says the child is not listening, and a teenager on high-dose cytarabine who skipped steroid eye drops are sensory-effect patients.

Platinum and radiation ototoxicity

Cisplatin and, to a lesser extent, carboplatin cause sensorineural ototoxicity. Injury starts at high frequencies (classically 8000 Hz and above on a pure-tone audiogram) and can march downward into the speech range. Young age, higher cumulative platinum, concurrent cochlear radiation , renal impairment, and prior hearing loss raise risk. The child may not report hearing loss. Toddlers stop turning to a whisper; school-age children crank the tablet, fail a hearing screen, or develop tinnitus . Vincristine is not the main ototoxin; it rarely causes other cranial-nerve palsies (ptosis, diplopia, vocal-cord or jaw problems) taught in the neurologic chapter. Do not skip platinum audiology because the vincristine jaw-pain talk already happened.

Radiation to the cochlea (posterior-fossa fields for medulloblastoma, nasopharyngeal or temporal fields, TBI) adds risk alone and synergizes with platinum. Do not invent a single cochlear gray threshold as ONCC fact. Teach field plus platinum plus serial testing.

Supportive audiology is the intervention: baseline and protocol-timed audiograms (or auditory brainstem response in infants who cannot condition), early hearing aids when indicated, and classroom FM systems so the teacher’s voice reaches the ear above noise. Preferential seating, captioning, and an individualized education program or 504 plan overlap the neurocognitive chapter; hearing loss is not inattention. Otoprotectants such as sodium thiosulfate appear on selected cisplatin protocols as ordered—do not add them yourself and do not quote an invented preservation rate.

A 7-year-old after cisplatin and posterior-fossa radiation who is failing spelling tests with a normal Glasgow Coma Scale still needs an audiogram. Processing-speed late effects and high-frequency loss can coexist; one does not cancel the other.

Eyes: steroids, cytarabine, GVHD, retinoblastoma, and papilledema

Corticosteroid cataracts (often posterior subcapsular) are a chronic and late lens effect of prolonged dexamethasone or prednisone . Blurred vision, glare, and declining chalkboard reading are clues. Ophthalmology follows; do not tell the family that pediatric cataracts cannot happen.

High-dose cytarabine causes chemical conjunctivitis and keratitis : photophobia, tearing, eye pain, and a child who refuses to open their eyes in a bright room. Prophylactic steroid eye drops (and sometimes saline rinses) start before the infusion and continue for the protocol window after. Missed drops are a nursing failure. Dim the lights, report pain, and do not label this as behavior. The chemotherapy chapter names the same drops; this section is the organ toxicity when they are skipped.

Chronic GVHD produces sicca — dry eyes , dry mouth—months after allogeneic HSCT. Artificial tears, humidification, and ophthalmology (including infection risk on a dry cornea) are the plan. This is the same sicca cluster named in the HSCT chapter; here the organ is the eye.

Retinoblastoma treatment can include enucleation, focal therapy, systemic or intra-arterial chemotherapy, and historically external-beam radiation. Visual outcome depends on laterality, intraocular group, and which eye was saved. After unilateral enucleation , the remaining eye is precious: eye protection, infection teaching, and prompt ophthalmology for new redness. Do not invent a single percentage of normal vision as ONCC fact. Bilateral disease is a lifelong visual-function problem, not only a tumor-staging problem from the solid-tumor chapter.

Papilledema (blurred optic disc, visual change, headache, morning vomiting) is a sign of increased ICP until proven otherwise—brain tumor, hydrocephalus, thrombosis. Signpost to the emergency ICP pathway. It is not a routine steroid-cataract clinic visit and not a reason to add extra dexamethasone at home.

Radiation retinopathy is a rare , delayed retinal vascular injury after orbital or cranial radiation. It is not an expected finding on day 1 of cranial radiation. New visual loss years later still needs ophthalmology rather than a shrug.

Nursing: what to report

Teach families and chart a short list. Report new hearing loss , tinnitus , photophobia , and eye pain the same day they appear during platinum, cytarabine, or GVHD windows—not at the next annual survivorship visit. Hold bright lights for keratitis, protect the residual eye after retinoblastoma treatment, and send the student who is not listening to audiology instead of a purely behavioral plan.

  • Effect Typical trigger Nursing focus
  • High-frequency then speech-range SNHL Cisplatin more than carboplatin Serial audiology; report tinnitus
  • Cochlear radiation injury Posterior fossa, nasopharynx, TBI Additive to platinum
  • Classroom hearing support Either ototoxin FM systems, seating, 504 or IEP
  • Vincristine cranial-nerve palsy Vinca (rare) Diplopia or ptosis; not the platinum audiogram
  • Steroid cataracts Prolonged dexamethasone or prednisone Vision change; ophthalmology
  • Cytarabine keratitis High-dose cytarabine Prophylactic steroid drops
  • GVHD dry eyes Allogeneic HSCT Tears, ophthalmology
  • Retinoblastoma visual outcome Local therapy, enucleation, historic RT Protect remaining vision
  • Papilledema Increased ICP Emergency signpost
  • Radiation retinopathy Rare, delayed Not day-1 cranial RT

The CPHON product is an audiogram that was not deferred until conversational speech collapsed, an FM system on a school 504 plan, cytarabine drops that went in before the infusion, and a nurse who treats photophobia and tinnitus as organ toxicity rather than screen-time complaints.

Loading diagram... Ophthalmologic and otologic effects: platinum hearing, cytarabine eyes, and ICP signpost